Edwards Lifesciences (EW) Faces FTC Penalty, Is The Stock Still Cheap?
Regulatory shock puts Edwards Lifesciences stock under a sharper lens
The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical, along with new restrictions on future TAVR AR deals, has pushed the stock’s regulatory risk profile into sharper focus.
See our latest analysis for Edwards Lifesciences.
Since the FTC action, Edwards Lifesciences’ recent 1 day share price return of 2.4% and 7 day return of 7.03% show selling pressure building, although the 12.08% 1 year total shareholder return points to a stronger longer term picture.
If this regulatory setback has you reassessing your healthcare exposure, it could be a good moment to scan other opportunities in medical technology using the 39 healthcare AI stocks
Edwards Lifesciences now trades about 12% below one estimate of intrinsic value and roughly 15% below the average analyst target, yet the stock also carries fresh regulatory constraints. Is that discount generous, or just cautious enough?
Most Popular Narrative: 13.3% Undervalued
Compared with Edwards Lifesciences' last close at $85.73, the most followed narrative points to a fair value of $98.92, supported by detailed revenue, earnings, and margin assumptions under a 7.43% discount rate.
The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
Curious what kind of revenue curve, profit margin lift, and future earnings multiple are baked into that $98.92 figure? The narrative leans on a specific growth path, richer profitability, and a valuation profile that assumes investors will keep paying up for Edwards Lifesciences' structural heart franchise.
Result: Fair Value of $98.92 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story of Edwards Lifesciences can shift quickly if tariff costs weigh more heavily on margins or if competitive pressure in key markets slows TAVR procedure growth.
Find out about the key risks to this Edwards Lifesciences narrative.
Another view on Edwards Lifesciences valuation
The narrative and DCF style estimate suggest Edwards Lifesciences is about 13.3% undervalued, yet the current P/E of 45.9x tells a different story. That is well above the US Medical Equipment industry on 27.5x, peers on 26.1x, and the stock’s own fair ratio of 31.5x.
Put simply, Edwards Lifesciences trades on a much richer earnings multiple than both its sector and the P/E level the regression model suggests the market could move toward, which may mean less room for error if earnings or sentiment soften from here.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern around Edwards Lifesciences leaves you uncertain, take a closer look at the underlying data now and weigh both sides of the story by reviewing the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Edwards Lifesciences?
Do not stop with Edwards Lifesciences. Broaden your watchlist now with focused stock ideas that could sharpen your portfolio and highlight opportunities you might otherwise miss.
- Target income by reviewing companies in the 8 dividend fortresses that may appeal if you want yields backed by stronger fundamentals.
- Look for potentially mispriced quality by scanning the screener containing 20 high quality undiscovered gems before other investors focus on them.
- Prioritise resilience by assessing companies in the 84 resilient stocks with low risk scores that may offer smoother performance when markets are volatile.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com